Navigation Links
Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development
Date:3/11/2008

STRASBOURG, France, March 11 /PRNewswire-FirstCall/ -- Transgene (Euronext Paris: FR0005175080) announces today its achievements in operations, financial performance for 2007 and outlook for 2008.

"2007 was a breakthrough year for Transgene, marked by two major accomplishments: the signing of a partnership agreement with Roche in the domain of therapeutic vaccines for the treatment of diseases caused by the HPV virus, and the successful completion of a EUR100.1m capital increase on European markets," declared Philippe Archinard, Managing Director of Transgene.

Key financial highlights include:

- Total revenues for the year were EUR28million compared to EUR5.5m in 2006.

- Transgene closed the year with a net loss of EUR5.5m compared to a net loss of EUR22m a year earlier.

- Basic loss per ordinary share was EUR0.28 versus EUR1.41 in 2006.

- Research and development expenditures were EUR28.8m compared to EUR24.2m in 2006.

- In 2007, net cash expenditure, excluding capital increase, was EUR5.5m compared to EUR20.7m in 2006.

- At the end of 2007, the company held cash and cash equivalents of EUR111.3m, which should enable it to finance some four years of operating costs.

Major Accomplishments of 2007:

Partnership Roche /Transgene: announced in April 2007, an exclusive world wide license agreement aimed at the development, registration and commercialisation of Transgene's therapeutic vaccines developed to fight diseases caused by the Human Papilloma Virus. Transgene received an upfront payment and a regulatory milestone of EUR23m in June 2007 and may receive further payments of up to EUR195m covering clinical development milestones and commercial milestones based on future sales of HPV products, stemming from Transgene's research. Under the terms of the agreement, Transgene is also entitled to receive progressive, double digit royalties on all future sales.

Strengthening of the Equity Bas
'/>"/>

SOURCE Transgene S.A.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
2. Transgene: Cash Position of EUR 119 Million as of September 30, 2007
3. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
4. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
5. Medline and 3M Agree to Strategic Partnership in Electrosurgery
6. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
7. B-Line Medical and Immersion Medical Announce Partnership
8. Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
9. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
10. ExonHit and bioMerieux Amend Their Strategic Partnership
11. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...., Dec. 3 Inverness Medi...der in enabling individuals to take charge of thei...ostics and health management, has declared a divid... Perpetual Preferred Stock ( IMA-PB). The dividend...ount per share equal to the quotient of (a) $3.00 ...
(Date:12/3/2009)...W DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Su...henzhen Beike Biotechnology Co. Ltd.,( http://www....-Risk Diabetic,Foot Care in New Delhi, India, Nove...research and regenerative medicine company. ,...try Association (IPA), aimed,to help podiatrists a...
(Date:12/2/2009)...ines, Dec. 2 Spectrum Blue Steel i...rgy companies on the planet. Through the efforts o...President and Recycling Specialist Leroy Johnston,...5 years, stated that Spectrum Blue Steel is light ...or spectacular earnings because of the bi products...
(Date:12/2/2009)...K, Dec. 2 Reportlinker.com announc...in its catalogue: ,, Carbondioxide Incubators ...eportlinker.com/p0164368/Carbondioxide-Incubators-...ors are the most critical equipment used in microb...ications for providing a controlled environment to...
Breaking Biology Technology:Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
...8 Kosan Biosciences,Incorporated (Nasdaq: KOSN )...and nine months ended September 30, 2007. Net los...30, 2007 were,$11.1 million and $19.2 million, or ...net loss of $7.5 million and $24.9 million, or $0....ear. Revenues were $1.9 million and $17.1 million...
... Inverness Medical,Innovations, Inc. (Amex: IMA ...ject to market and other conditions, 7,000,000 sha...helf registration statement in an,underwritten pub...Company,are also offering to sell up to 165,698 sh...expects to grant the underwriters a 30-day option ...
... Inverness Medical,Innovations (Amex: IMA ) toda...with Chemogen, Inc. for the worldwide manufacture ...of Mycobacterium, the primary,causative agent of t...prietary antibodies for the detection of Lipoarabi...iagnosis of current mycobacterial infection,(inclu...
Other Biology Technology:Kosan Announces Third Quarter 2007 Financial Results 2Kosan Announces Third Quarter 2007 Financial Results 3Kosan Announces Third Quarter 2007 Financial Results 4Kosan Announces Third Quarter 2007 Financial Results 5Kosan Announces Third Quarter 2007 Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 7Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 2Inverness Medical Innovations Announces Proposed Public Offering of Common Stock 3Inverness - Chemogen Establish Exclusive License for TB Antibodies 2
(Date:12/3/2009)... , The UK leads the world when it comes to invest...t Engineering and Physical Sciences Research Counc...t more is needed: "Scientific and engineering rese...nd and solar power solutions, but more investment ... solutions if we are to meet our carbon emission t...
(Date:12/2/2009)... , , PHILADELPHIA Children exposed to secondhand...ing lung cancer in adulthood, even if they never s... Cancer Epidemiology, Biomarkers & Prevention , a...search, as part of a special tobacco focus in the ...9,000 Americans will be diagnosed with lung cancer...
(Date:12/2/2009)... , , PHILADELPHIA Cigarette smoking and alcohol ...strongly predicts the patient,s future risk of dea...f a new study show a similar effect among those wh..., "Most cancer survivors are counseled to quit sm...y, 21 percent continued to smoke even after their ...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Fox Soccer Channel and Fox Sports en Espanol Renew Every Goal Saves A Life Campaign With Malaria No More 55723 1Fox Soccer Channel and Fox Sports en Espanol Renew Every Goal Saves A Life Campaign With Malaria No More 55723 2Fox Soccer Channel and Fox Sports en Espanol Renew Every Goal Saves A Life Campaign With Malaria No More 55723 3Fox Soccer Channel and Fox Sports en Espanol Renew Every Goal Saves A Life Campaign With Malaria No More 55723 4New Technology Helps Athletes Prevent Dehydration and Heat Related Illness 55720 1New Technology Helps Athletes Prevent Dehydration and Heat Related Illness 55720 2Secca 28R 29 Therapy An Effective and Minimally Invasive Option for Treating Bowel Incontinence Launched in the US 55717 1Secca 28R 29 Therapy An Effective and Minimally Invasive Option for Treating Bowel Incontinence Launched in the US 55717 2
...ide to make proteins, key building blocks of all o... the instructions for assembling them. , An Iowa...hanism involved in marking where these instruction...dition of The Journal of Biological Chemistry , M...emistry, biophysics and molecular biology, along w...
...-- Researchers at Weill Cornell Medical College in... date palm genome, unlocking many of its genetic s... and initial assembly of the date palm using the m...r of the Genomics Laboratory at Weill Cornell Medi...e date palm is extremely valuable to researchers w...
...t evolution and creationism are often shaped by wh...es, according to a University of Minnesota study p...rnal of the American Institute of Biological Scien...professors in the College of Biological Sciences, ...y classes at the University of Minnesota to learn ...
Other Biology News:Genetic secrets of date palm unlocked by researchers at Weill Cornell Medical College in Qatar 2U of Minnesota study finds high school teachers influence student views of evolution & creationism 2
Yeast-GFP Collection from Invitrogen
...s can be used for the identification of potential ...r renal and other diseases. Due to the fact that u...nts, it provides an attractive alternative to bloo...rs. The ProteoSpin Urine Protein Concentration Mi...
... has joined forces with the Mickle Laboratory Engi...Tissue Chopper. This tissue sectioning system has ...tabolic experiments and to be especially applicabl...opsy or from small organs. Its special features ca...
Yeast-GFP 96-well Plates from Invitrogen
Biology Products: